Chemotherapy Plus Lapatinib or Trastuzumab or Both in Her2+ Primary Breast Cancer. A Randomized Phase IIb Study With Biomarker Evaluation
Latest Information Update: 26 Sep 2023
At a glance
- Drugs Lapatinib (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil; Methotrexate; Paclitaxel; Trastuzumab
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms CHER-LOB
- Sponsors GlaxoSmithKline
- 07 Sep 2023 Results from ShortHER trial, CherLOB , evaluating how molecular heterogeneity affects the pattern of distant relapse in HER2-positive BC, published in the Journal of the National Cancer Institute
- 18 Jun 2021 Results of post-hoc survival analysis assessing long-term survival outcomes published in the European Journal of Cancer
- 31 May 2020 Primary endpoint (Percentage of Participants With Pathological Complete Response (pCR) in the Breast and in the Lymph Nodes) has been met, as per Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology